Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bactiguard Holding ABCHIX:BACTBS 61 Debt-to-EBITDA is 11.65 as of Jun. 2026, which is 164% above its 10-year median of 4.41. GuruFocus rates CHIX:BACTBS with a GF Score™ of 61/100 and a GF Value™ of kr254.71. The stock has 2 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Bactiguard Holding AB ranks worse than 70.88% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bactiguard Holding AB's Debt-to-EBITDA or its related term are showing as below:
CHIX:BACTBs'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -124.45 Med: 4.41 Max: 23.64
Current: 3.11
During the past 13 years, the highest Debt-to-EBITDA Ratio of Bactiguard Holding AB was 23.64. The lowest was -124.45. And the median was 4.41.
CHIX:BACTBs's Debt-to-EBITDA is ranked worse than 70.88% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs CHIX:BACTBs: 3.11
Bactiguard Holding AB (CHIX:BACTBs) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bactiguard Holding AB Debt-to-EBITDA Related Terms
Bactiguard Holding AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Bactiguard Holding AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BACTBS vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Bactiguard Holding AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bactiguard Holding AB Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bactiguard Holding AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bactiguard Holding AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Bactiguard Holding AB (CHIX:BACTBS) has a Debt-to-EBITDA of 11.65 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bactiguard Holding AB. This is 164% above median its historical median of 4.41. According to the industry distribution chart, Bactiguard Holding AB ranks #331 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 70.9%.
Is Bactiguard Holding AB's Debt-to-EBITDA too high?
Bactiguard Holding AB's current Debt-to-EBITDA of 11.65 is 164% above median its 10-year median of 4.41. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. Bactiguard Holding AB's value of 11.65 is 642% above this industry median. Based on the distribution chart, Bactiguard Holding AB ranks #331 out of 467 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bactiguard Holding AB has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Bactiguard Holding AB's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bactiguard Holding AB ranks #331 out of 467 companies for Debt-to-EBITDA. This places Bactiguard Holding AB in the lower half of its industry. The industry median Debt-to-EBITDA is 1.57. Bactiguard Holding AB's value of 11.65 is 642% above this benchmark. While the company's 10-year median is 4.41 vs. the industry median of 1.57, Bactiguard Holding AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bactiguard Holding AB's current Debt-to-EBITDA of 11.65 is 642% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bactiguard Holding AB. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bactiguard Holding AB's current Debt-to-EBITDA is 11.65, which is 164% above median its own 10-year median of 4.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bactiguard Holding AB stock overvalued right now?
Bactiguard Holding AB (CHIX:BACTBS) has a current Debt-to-EBITDA of 11.65. The stock's GF Value™ is kr254.71, compared to a current price of kr128.60 — trading 49.5% below its estimated fair value. The current Debt-to-EBITDA is 11.65, which is 164% above median its 10-year median of 4.41 and 642% above the Medical Devices & Instruments industry median of 1.57. Bactiguard Holding AB's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bactiguard Holding AB (CHIX:BACTBS), the current Debt-to-EBITDA is 11.65 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bactiguard Holding AB (CHIX:BACTBS) Overvalued in 2026?
Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued.
The current stock price of kr128.60 is trading 49.5% below its estimated GF Value™ of kr254.71.
Key valuation signals for CHIX:BACTBS:
Debt-to-EBITDA: 11.65 (164% above median its 10-year median of 4.41)
GF Value™: kr254.71 vs. price of kr128.60 (49.5% below fair value)
Industry Position: 642% above the Medical Devices & Instruments median (#331 of 467)
No single metric tells the full story. See the CHIX:BACTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
61GF Score
Get the complete analysis for CHIX:BACTBS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BACTBS has been successfully added to your 
